Tech Company Financing Transactions

Alterome Therapeutics Funding Round

Goldman Sachs, Blue Owl Capital and Canaan Partners participated in a $132 million Series B funding round for Alterome Therapeutics. The round was announced on 4/3/2024.

Transaction Overview

Announced On
4/3/2024
Transaction Type
Venture Equity
Amount
$132,000,000
Round
Series B
Proceeds Purpose
The company said in a statement that the proceeds will be used to "support the advancement of multiple wholly-owned pipeline programs," including two precision oncology programs into clinical development within 12 months.

Company Information

Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
13480 Evening Creek Drive North 450
San Diego, CA 92128
USA
Phone
Undisclosed
Email Address
Overview
Our Mission is to discover precise therapies and inspire hope for individuals affected by cancer. We are driven by the urgency of our mission and guided by our core values of accountability, creativity, perseverance, longevity, exemplifying compassion, and a mind toward co-elevation.
Profile
Alterome Therapeutics LinkedIn Company Profile
Social Media
Alterome Therapeutics Company Twitter Account
Company News
Alterome Therapeutics News
Facebook
Alterome Therapeutics on Facebook
YouTube
Alterome Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Eric Murphy
  Eric Murphy LinkedIn Profile  Eric Murphy Twitter Account  Eric Murphy News  Eric Murphy on Facebook
Chief Marketing Officer
Andrew Chi
  Andrew Chi LinkedIn Profile  Andrew Chi Twitter Account  Andrew Chi News  Andrew Chi on Facebook
Chief Medical Officer
Vicky Kang
  Vicky Kang LinkedIn Profile  Vicky Kang Twitter Account  Vicky Kang News  Vicky Kang on Facebook
Chief Medical Officer
Xuefeng Zhu
  Xuefeng Zhu LinkedIn Profile  Xuefeng Zhu Twitter Account  Xuefeng Zhu News  Xuefeng Zhu on Facebook
Chief Operating Officer
Scott Moorefield
  Scott Moorefield LinkedIn Profile  Scott Moorefield Twitter Account  Scott Moorefield News  Scott Moorefield on Facebook
Vice President
Michael Bartberger
  Michael Bartberger LinkedIn Profile  Michael Bartberger Twitter Account  Michael Bartberger News  Michael Bartberger on Facebook
VP - Bus. Development
Joe Juan
  Joe Juan LinkedIn Profile  Joe Juan Twitter Account  Joe Juan News  Joe Juan on Facebook
VP - Finance
America Thompson
  America Thompson LinkedIn Profile  America Thompson Twitter Account  America Thompson News  America Thompson on Facebook
VP - General Counsel
Jim Cartoni
  Jim Cartoni LinkedIn Profile  Jim Cartoni Twitter Account  Jim Cartoni News  Jim Cartoni on Facebook
VP - Human Resources
Brittany Shea
  Brittany Shea LinkedIn Profile  Brittany Shea Twitter Account  Brittany Shea News  Brittany Shea on Facebook
VP - Operations
Dana Peters
  Dana Peters LinkedIn Profile  Dana Peters Twitter Account  Dana Peters News  Dana Peters on Facebook
VP - Operations
Breda Walsh
  Breda Walsh LinkedIn Profile  Breda Walsh Twitter Account  Breda Walsh News  Breda Walsh on Facebook
VP - Product Management
Andrew Phimister
  Andrew Phimister LinkedIn Profile  Andrew Phimister Twitter Account  Andrew Phimister News  Andrew Phimister on Facebook
VP - Regulatory Affairs
Aziz Alam
  Aziz Alam LinkedIn Profile  Aziz Alam Twitter Account  Aziz Alam News  Aziz Alam on Facebook


 

 

Browse more venture capital transactions:

Prev: 4/3/2024: Brim Financial venture capital transaction
Next: 4/3/2024: Higgsfield AI venture capital transaction

 

Share this article

 


Where The Data Comes From

Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary